National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. - Wikidata - wikimedia - TriplyDB

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

http://www.wikidata.org/entity/Q34382878

about

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical Ponatinib in refractory Philadelphia chromosome-positive leukemias.Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia On the Use of Local Assessments for Monitoring Centrally Reviewed Endpoints with Missing Data in Clinical Trials Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing High mitochondrial DNA stability in B-cell chronic lymphocytic leukemia National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data Alemtuzumab in chronic lymphocytic leukemia The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.The impact of hepatitis viruses on chronic lymphoproliferative disorders--preliminary results Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.Correlations of hematological parameters with bone marrow findings in chronic lymphoproliferative disorders associated with hepatitis viruses.Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

P2860

Q24336378-040367C5-C1E2-4861-8621-A8477023B6BC Q24616084-6A11A8C7-CD46-499A-BF5D-C0E8B1748D7F Q24675399-0EBDCB88-0D22-41A7-B5A7-21104BBC875D Q24681296-25F5059A-4316-4FD7-BCF2-658C042A4E03 Q24681992-61326F3F-7E72-4CF1-B8AA-FE73AD9A1620 Q27851967-F93B458D-9BDA-41E5-995B-E0F9334F3677 Q28082120-D8486B27-B130-4EC1-B911-704E1D315BBE Q28261949-EB75BBBD-4124-433C-A2E4-6D6F96225799 Q28649448-2C89CA13-5F3C-4A00-80A4-A776231F60B4 Q29048163-BA6B656F-E8D3-45A0-B0D9-D665843691D3 Q30408922-248F2AA1-8D53-455B-A78E-D87A72702F32 Q30466798-DE98D802-0E92-4137-8615-898AC085B848 Q30896674-05473058-3764-402E-92BE-B02D3AD4F412 Q31147343-A6E16250-65AB-4CB3-A62F-B020909C5AC4 Q33288974-A24F2682-9E65-4F6F-84F2-0A61F43270BD Q33379107-F5EF0F34-44C0-4384-B23F-3569CE81C533 Q33379565-00121F86-E4D2-469C-9F42-FFBF474F926C Q33381678-8F03470A-A540-4018-922A-F8C61DCF1B66 Q33382608-F217FC51-3CC0-44AC-9103-04C2C43E6C89 Q33385566-6ECFAD25-6761-4380-96EC-BCEF7D0B02D1 Q33385670-5AD45A66-33C6-4E7B-835D-6BBB077C27B2 Q33386193-6785C29E-2CFE-4570-9755-CD60B3701986 Q33386533-5A81B3FF-AEBA-40E0-BD47-625CBDCC96CE Q33388795-2714FA3A-C823-4538-B284-8A3F54CAA4D6 Q33389485-925D9C74-A753-4A06-866C-9668FE6F52F0 Q33392295-FE778857-B719-4ACC-B41B-D22B983C124B Q33394487-03806D1C-BA56-4B86-A807-DF5591A752F8 Q33394947-CF001DBF-4C2A-485E-86EA-C3072ADD2D06 Q33396222-75F06F59-601C-4E0A-BC51-98425B0DAC93 Q33398808-3900E6F6-3FA0-40D9-8C12-B1D2C1265A3F Q33415564-AA77D3E5-02CA-452D-A3E6-B72B482F3B58 Q33421376-6846011D-5765-4990-B12E-0F6982CA9C78 Q33424781-797039AD-EBE5-4B3C-942A-A5AF6BA8C6D4 Q33439333-F426898D-32B6-4ED1-BC7E-03FC7E958E0D Q33558148-1B5CE6E7-71FB-4FF3-9779-3AA64CCB44B2 Q33558740-A63B30E5-473E-4E08-BA30-A43C895407E8 Q33573355-93943B80-9386-4AB0-853A-5E3AC951E0F5 Q33590562-3485DCA4-E6B1-4B07-8F17-A18E5F452DFA Q33598691-4F96F909-ACCD-4560-88F7-B622095968C4 Q33627721-F27A8FBE-41E6-4A54-A627-CBB926ACF4CD

P2860

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

http://www.wikidata.org/entity/Q34382878

description

1996 nî lūn-bûn

@nan

1996 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

National Cancer Institute-spon ...... s for diagnosis and treatment.

@ast

National Cancer Institute-spon ...... s for diagnosis and treatment.

@en

National Cancer Institute-spon ...... s for diagnosis and treatment.

@nl

type

label

National Cancer Institute-spon ...... s for diagnosis and treatment.

@ast

National Cancer Institute-spon ...... s for diagnosis and treatment.

@en

National Cancer Institute-spon ...... s for diagnosis and treatment.

@nl

prefLabel

National Cancer Institute-spon ...... s for diagnosis and treatment.

@ast

National Cancer Institute-spon ...... s for diagnosis and treatment.

@en

National Cancer Institute-spon ...... s for diagnosis and treatment.

@nl

P1433

Q34382878-B019ACEB-EC37-486D-9192-FF2C50A0EC60

P1476

Q34382878-80822FCC-E30D-4E15-B60B-C07545E99BE9

P2093

Q34382878-0BE887F9-D2DB-47C1-A7CA-B0CE28BB24DC

Q34382878-0CEA9BBD-ED6B-48DA-BE2E-2881FC69E2D2

Q34382878-63FE4B3E-77A6-4A45-A2D4-1D6478530BCF

Q34382878-6798D8C3-655B-475D-89C1-143FA89135D9

Q34382878-7208D0C5-420F-4028-A30D-9A1B77F4E5CD

Q34382878-B512330F-7941-4064-975F-DEE81C6ABBD9

Q34382878-E2CE171C-26FB-41D3-B30E-FC6E5F22788B

P304

Q34382878-8FB0207A-DC91-4DFF-927F-E3AD87E3EEA1

P31

Q34382878-77B49AFF-AAC5-4F0B-9DE2-B6A003ABDC1E

P407

Q34382878-578B9DF2-550C-45AC-9580-4DECACE766EF

P433

Q34382878-83751FC3-240C-4B19-A91B-68AF21DC8073

P478

Q34382878-94A50CCC-9249-4496-92F2-94A8C5F7F1A7

P577

Q34382878-24FD5CA4-6D78-49C1-AC23-2CD5CD4A6073

P698

Q34382878-B4C58966-8C30-458C-B86A-D2919A6388EA

P921

Q34382878-596907FF-3415-4D27-96C2-E6C5925D1744

Q34382878-8883347A-BAA5-44C4-8E16-817AE9650F61

Q34382878-96b371eb-3474-440d-aad5-2f4afa2fd22c

P1433

P1476

National Cancer Institute-spon ...... s for diagnosis and treatment.

@en

P2093

Bennett JM

http://www.w3.org/2001/XMLSchema#string

Cheson BD

http://www.w3.org/2001/XMLSchema#string

Grever M

http://www.w3.org/2001/XMLSchema#string

Kay N

http://www.w3.org/2001/XMLSchema#string

Keating MJ

http://www.w3.org/2001/XMLSchema#string

O'Brien S

http://www.w3.org/2001/XMLSchema#string

Rai KR

http://www.w3.org/2001/XMLSchema#string

P304

4990-4997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

1996-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8652811

http://www.w3.org/2001/XMLSchema#string

P921